Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABC-Maint: Chidamide, Venetoclax, and Azacitidine Maintenance in AML
NCT07521124Not yet recruiting
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tucidinostat in acute myeloid leukemia (AML) (2 cohorts). Primary endpoint: Relapse-Free Survival at 1 year. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07521124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07521124.